阿托伐他汀强化治疗冠心病患者血脂异常的临床疗效

Clinical efficacy of an intensive atorvastatin therapy in coronary heart disease patients with dyslipidemia

目的比较阿托伐他汀每日服20与10mg治疗冠心病伴高胆固醇血症患者的疗效和安全性。方法入选病例60例随机分为2组,A组30例,每晚口服阿托伐他汀20mg;B组30例,每晚口服10mg。治疗8wk。治疗前后分别测定血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C),并观察患者的不良反应。结果60例均完成试验。2组治疗前各项血脂基线值差异无统计学意义,而治疗前后TC、TG、LDL-C下降值比较差异有统计学意义(P<0.05)。治疗过程中无严重不良事件。结论阿托伐他汀20mg治疗冠心病伴高胆固醇血症安全且更加有效。

AIM To compare the efficacy and safety of atorvastatin 20 mg daily with atorvastatin 10 mg daily in coronary heart disease （CHD） patients with hypercholesterolemia. METHODS Sixty CHD patients with hypercholesterolemia were randomized into either group A or group B. Thirty cases in group A were administrated with atorvastatin 20 mg and the others in group B were administrated with atorvastatin 10 mg daily for 8 wk. Total cholesterol（TC）, trigly cerides（TG）, high-density lipoprotein cholesterol（ HDL-C）and low-density lipoprotein cholesterol（LDL-C） of the patients were tested at baseline, 8 wk, respectively. The adverse drug reactions were observed. RESULTS Sixty cases completed the test. TC, TG, HDL-C and LDL-C were no significantly differences at baseline between 2 group . After 8 wk, the decreasing part of TC,TG and LDL-C in group A were significantly more than that in group B（1.83 ± 0.85 vs 1.31 ±0.77,0.46 ±0.15 vs 0. 32 ± 0.19,1.81 ± 0.53 vs 1.46 ± 0.67 rnmol· L^-1, respectively, P 〈 0.05）. No severe adverse everts of atorvastatin were seen in the course of the treatment. CONCLUSION Atorvastatin 20 mg daily can decrease TC, TG, LDL-C levels of CHD patients with dyslipidemia safely and more efficently.